Compass Therapeutics Reports Q2 Net Loss of $19.9mln

Compass Therapeutics reported a Q2 net loss of $19.9 mln, widening from the previous quarter. The company has been adding to various Russell indexes, including the Russell 3000 Growth Index, and has announced several clinical trial updates, including the dosing of the first patient in an investigator-sponsored trial of Tovecimig in biliary tract cancer.

Compass Therapeutics (CMPX) reported its Q2 2025 financial results, showing a net loss of $19.9 million, up from $13.1 million in Q2 2024 [2]. The company has been adding to various Russell indexes, including the Russell 3000 Growth Index, and has announced several clinical trial updates. The company's Chief Executive Officer, Thomas Schuetz, MD, PhD, highlighted key developments during the quarter.

The company reported promising survival data for tovecimig in biliary tract cancer, with secondary endpoint analysis now expected in Q1 2026. In the CTX-8371 Phase 1 trial, two significant partial responses were observed in post-checkpoint inhibitor settings, including 100% tumor reduction in a lung cancer patient and 90% reduction in a breast cancer patient [2]. Additionally, the company's new drug CTX-10726 showed superior results compared to ivonescimab in preclinical studies [2].

Compass Therapeutics ended Q2 with $101 million in cash, providing runway into 2027. R&D expenses increased 47% year-over-year to $16.4 million, primarily due to manufacturing costs for tovecimig and CTX-10726 [2]. The company's diversified pipeline targeting multiple cancer pathways (angiogenesis, immune checkpoints, co-stimulatory molecules) represents a sophisticated strategy that could yield multiple opportunities for success in difficult-to-treat solid tumors.

The company will host a webcast and conference call on August 11, 2025, at 8:00 AM ET, to provide further insights into its financial results and ongoing developments. Investors can join the call via webcast or by dialing 1-877-407-9716 within the US, or 1-201-493-6779 for international callers, using the conference ID 13754954. A replay of the webcast will be available for 90 days post-event on Compass' Events page [1].

References:
[1] https://www.gurufocus.com/news/3050651/compass-therapeutics-to-present-second-quarter-financial-results-and-provide-business-update-on-august-11-2025--cmpx-stock-news
[2] https://www.stocktitan.net/news/CMPX/compass-therapeutics-reports-2025-second-quarter-financial-results-tds7rwxcoc0n.html